The new Chief Operating Officer for Kuano is Denise Moody

Cambridge, U.K., 15 August 2022 – Kuano Ltd announced today the appointment of Denise Moody as Chief Operating Officer (COO).

Denise Moody brings to Kuano more than 30 years’ experience in the healthcare sector where she has built and led highly successful project teams in R&D, post-approval and legacy transfer projects with values in excess of $100 million.

“I am delighted to welcome Denise as our Chief Operating Officer” said Vid Stojevic, Kuano’s CEO. “Looking at our potential in drug discovery and our growth plans, experience and execution are of the essence. Denise’s leadership and extensive knowledge of the industry will be key factors for Kuano’s success.”

As COO, Ms Moody will lead Kuano’s key functions, including Product Development and Programme Management.

“I am excited to be working with this talented and enthusiastic team. Kuano has an amazing potential in a very hot space, where the need for highly selective and effective medications is constantly increasing. These are the challenges I like.”

In addition to her recent role as COO at Cycle Pharmaceuticals, Ms Moody has held previous roles in various Pharmaceutical companies including Astra Zeneca, Roche, Bayer, Hexal, Actavis and served for 5 years at PPD, one of the largest global Clinical Research Organisations, setting up their Functional Service Partnership (FSP) division.